Most discussions of why PRP protocols fail go straight to technique — depth, spacing, session count. Those matter, and they are covered elsewhere in this cluster. But a substantial share of disappointing platelet-rich plasma outcomes are decided before the injecting needle is ever uncapped, in the twenty minutes between the tourniquet going on and the product being drawn into the syringe.
Laboratory medicine has a name for this category. Pre-analytic variables are everything that happens to a specimen before the assay runs, and in clinical chemistry they are recognised as the largest single source of error — larger than the analysis itself. PRP is unusual in that the specimen and the drug are the same object. Every pre-analytic variable that would corrupt a laboratory result corrupts the therapeutic product instead, and unlike a bad lab result, a weak PRP preparation does not flag itself. It looks identical in the syringe. You find out three months later, from a patient who did not respond.
Tatiana Sarmiento puts the category on her list of what sinks a hair programme, in one compressed line: "Inconsistency in prep. You are using a different kind of machine. You're not using the right concentration. The patient was dehydrated — that's something that makes a lot of influence in the result."
That is one sentence covering three separate failure domains. This resource unpacks all three, in the order the specimen encounters them.
Domain one: the draw
The venipuncture is the first opportunity to change the product, and it is the step most likely to be delegated without a written standard.
Tourniquet time. Prolonged tourniquet application produces local haemoconcentration — fluid shifts out of the vessel under venous pressure and the cellular fraction of what you aspirate rises. Standard phlebotomy practice limits tourniquet time to under a minute for exactly this reason. When the tourniquet has been on for three minutes while someone hunts for a vein, the specimen entering the tube is not the same specimen that would have entered it at thirty seconds. Release the tourniquet once flow is established.
Needle gauge and aspiration force. Platelets are shear-sensitive. Drawing whole blood through an unnecessarily narrow bore, or pulling hard on a syringe plunger to force flow from a reluctant vein, subjects platelets to shear that can trigger premature activation and degranulation. A platelet that has already released its granule contents in the tube delivers nothing at the tissue. Use an adequate bore, let vacuum or gravity do the work, and stop pulling when the flow slows.
Traumatic draw and haemolysis. Repeated probing, excessive negative pressure and small-bore access all raise the risk of haemolysis. Visible pink discolouration of the plasma is a reject criterion in the laboratory and should be treated as one here.
Tube fill volume. This is the most under-appreciated error in the whole sequence. Anticoagulated collection tubes are formulated for a specific blood-to-anticoagulant ratio, and that ratio only holds if the tube is filled to its marked volume. An underfilled citrate tube carries a relative excess of anticoagulant against a reduced plasma volume, and that excess changes the ionic environment the platelets sit in. Fill to the line. A tube that stopped short because the vein collapsed is not a tube to process "anyway."
Mixing. Gentle inversion the specified number of times, immediately. Not shaking, which shears. Not skipping it, which lets clot initiation begin in a tube you are about to centrifuge.
Order of draw. If other tubes are being collected in the same sitting, observe standard order-of-draw so that additive carryover does not contaminate the PRP tube. A trace of EDTA carried into a tube you intend to reinject is a contamination event, not a rounding error.
Domain two: the anticoagulant
Anticoagulant choice is a specification, not a preference, and it belongs in the written protocol rather than in whatever the supplier happened to ship.
The agents commonly used for PRP intended for reinjection are acid citrate dextrose solution A (ACD-A) and sodium citrate. Both work by chelating calcium, which is reversible — calcium can be restored at the point of use if the protocol calls for activation. ACD-A additionally carries dextrose and a lower pH, and is widely used in apheresis for platelet preservation.
Two agents to think carefully about:
- EDTA chelates calcium irreversibly enough to be problematic, is associated with platelet morphological change, and is not the standard choice for a product that is going back into a patient.
- Heparin does not chelate calcium — it works through antithrombin — and heparin exposure is associated with platelet activation. It is not the conventional choice for aesthetic PRP.
The operational point is narrower than the pharmacology: do not change agents mid-protocol. A patient who received ACD-A-anticoagulated product for sessions one and two and citrate product for sessions three and four received two different preparations in a series you intend to evaluate as one intervention.
Domain three: the centrifuge — and the RCF trap
This is where Tatiana's "you are using a different kind of machine" does the most damage, and the mechanism is more specific than it sounds.
RPM is not a dose. RCF is.
What separates blood is relative centrifugal force, not rotational speed. The two are related by the radius of the rotor:
RCF = 1.118 × 10⁻⁵ × r × N²
where r is the rotational radius in centimetres and N is speed in revolutions per minute.
Because RCF scales with rotor radius, the same RPM on two different centrifuges produces two different forces. A protocol written as "3,200 RPM for 10 minutes" is not portable. Run it on a machine with a shorter rotor arm and you under-separate; run it on a longer arm and you over-pellet. The specification that transfers between machines is the one written in g.
This single point resolves most of the confusion that arises when a practice replaces a centrifuge, adds a second one, or borrows a protocol from a colleague who uses different equipment. If your written protocol contains an RPM and no g value, it is machine-specific and you did not know it.
Everything else about the machine matters too:
Rotor type. Fixed-angle and swing-out rotors produce differently shaped interfaces. A fixed-angle rotor deposits cells against the side wall and the boundary sits obliquely; a swing-out rotor gives a flat horizontal interface that is easier to harvest reproducibly. Switching rotor types changes the harvest even at identical RCF.
Acceleration and braking ramps. A hard brake at the end of a spin can disturb a freshly formed interface and remix layers you just separated. Where the centrifuge offers ramp control, the setting is part of the protocol.
Temperature. Chamber temperature affects platelet behaviour, and an unventilated machine running back-to-back cycles in a warm room is not operating where it was validated.
Balance. An imbalanced load vibrates, and vibration disturbs the interface. Balance by mass, with a counterweight tube, every time.
Drift and service. Centrifuges age. Motors slow, tachometers lose accuracy, timers run long or short. A machine that is out of calibration does not announce it — it just quietly produces a different product than the one your protocol specifies. Establish a service and verification interval with the manufacturer and log it. This is the "equipment drift" half of the problem, and it is invisible without deliberate checking.
Domain four: harvest — the operator variable
After the spin, somebody has to collect the layer. This is the most operator-dependent step in the entire sequence and it is almost never standardised in writing.
The variables are simple to state and hard to control by feel:
- How far into the plasma column you aspirate. Platelets are not evenly distributed in the supernatant; they concentrate toward the interface. Collecting the upper plasma preferentially yields a platelet-poor product; going deep captures more platelets and risks red cell and leukocyte carryover.
- How aggressively you aspirate. Fast aspiration creates turbulence at the interface and remixes what the centrifuge just separated. Slow and steady.
- Whether you disturb the buffy coat, which is the decision that determines leukocyte content — the specification covered in depth in the leukocyte-rich versus leukocyte-poor resource in this cluster.
- Who is doing it. Two clinicians in the same practice, using the same kit and the same machine, will produce measurably different products if the harvest is done by eye without a defined endpoint.
Define the endpoint in millimetres or in millilitres, not in adjectives. "Collect the plasma down to 2 mm above the interface" is a protocol. "Collect the good part" is not.
Domain five: switching systems
Tatiana's phrasing — "you are using a different kind of machine" — extends beyond the centrifuge to the whole preparation system, and it deserves stating as a principle.
A PRP system is a closed specification, and its components are not interchangeable. Tube geometry, separator gel or float design, anticoagulant, spin protocol and harvest method were validated together. Substituting one element because it was cheaper or because the usual supplier was out of stock invalidates the specification, even when every individual component is of good quality.
The clinical consequence is that a switch mid-series breaks the one thing a treatment series depends on: that each session delivers the same thing. If you must change systems, the honest options are to complete the current patient's series on the original system, or to reset the baseline — re-photograph, re-measure, and treat the switch as the start of a new evaluation period. Document the change and the lot numbers either way.
The same logic applies to the quieter version of the problem: running two systems simultaneously because different staff prefer different kits. That is not redundancy, it is two protocols in one practice. The same specification discipline is what separates platelet-rich plasma from the adjacent biologics a practice may also stock, compared in exosomes versus PDRN versus PRP.
Domain six: the patient as a variable
The final pre-analytic variable walks in the door.
Baseline platelet count. The concentration of platelets in a preparation is a multiple of what was in the whole blood. A patient at the low end of the normal range does not yield the same absolute platelet dose as a patient at the high end, even with an identical, perfectly executed protocol. This is a plain consequence of the arithmetic of concentration, and it is a reason to know a patient's count rather than to assume it.
Antiplatelet agents and NSAIDs. Platelets are the active ingredient and several commonly used drugs impair their function. A protocol should have a written position on what patients are asked to hold, for how long, and what is not safe to hold — anything prescribed for cardiovascular indications is a conversation with the prescribing clinician, never a unilateral instruction from an aesthetic practice.
Hydration status. This is the variable Tatiana names explicitly, and it deserves an honest treatment. The mechanism is straightforward: a dehydrated patient is haemoconcentrated, with a reduced plasma volume and a raised haematocrit. That changes the proportions of what enters the tube, changes where the interface forms, and reduces the plasma available to harvest. It also makes the venipuncture harder, which recruits every draw-related error in domain one.
What is not established is a demonstrated effect of pre-procedure hydration on clinical PRP outcomes. There is no outcome trial being cited here, and none should be implied. The defensible position is the one Tatiana takes at the chairside: hydration is a cheap, harmless, controllable variable that removes a known source of specimen variation, so standardise it. Instruct patients to be normally hydrated, schedule consistently relative to meals and caffeine if you can, and stop short of claiming that a glass of water changes the result.
Acute illness, recent infection, recent strenuous exercise. All shift blood counts transiently. If a patient arrives unwell, rescheduling costs one appointment; processing them anyway costs a data point in a twelve-month series.
What to standardise, and what to log
The corrective is unglamorous: convert the preparation from a practised habit into a written, versioned standard operating procedure, and log what you actually did.
Minimum content of the SOP:
- Tube type, additive and target fill volume, with the reject criteria.
- Draw technique — gauge, tourniquet limit, mixing inversions.
- Maximum permitted interval from draw to spin, and from spin to injection.
- Spin protocol expressed in RCF and minutes, with the RPM for your specific machine recorded alongside as a derived value.
- Rotor type, acceleration and brake settings.
- Harvest endpoint, defined dimensionally.
- Named staff authorised to perform each step.
- Centrifuge service and verification interval.
Minimum content of the per-session log, in the chart: date, operator, kit lot number, machine identifier, spin parameters used, volume harvested, and any deviation. When a patient does not respond, that log is the difference between a diagnosable problem and a shrug.
A periodic quality check closes the loop. Running a complete blood count on the whole blood and on the finished product, on a defined schedule, tells you the concentration factor your process is actually achieving rather than the one the brochure promised. It is the only way to detect drift before a patient does.
What to do differently
Rewrite the spin specification in g this week. Put a written harvest endpoint on the wall by the centrifuge. Log kit lot and machine on every session. Stop switching systems mid-series. Ask about hydration and antiplatelet agents at booking rather than at the chair. And schedule the centrifuge verification, because the machine will not tell you when it starts to drift.
These protocols and preferences reflect Tatiana Sarmiento's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
Preparation technique is taught hands-on in Empire's platelet rich plasma training, and in the hair-specific context in medical hair loss, PDO thread and PRP hair restoration training.
Related guides in this cluster
Part of Regenerative Injectables: PRP and PRF.
Clinical GuideSingle Spin vs Double Spin PRP: What Actually Changes in the TubeSingle spin vs double spin PRP compared for clinicians — what the second spin concentrates, why volume compensates, and how processing
Clinical GuideLeukocyte-Rich vs Leukocyte-Poor PRP: Matching Cell Content to the IndicationLeukocyte-rich vs leukocyte-poor PRP explained for clinicians — the cytokine data, the PAW, DEPA and Dohan Ehrenfest frameworks, and wh
Clinical GuideDiagnose Before You Treat: The Hair Loss Workup That Must Precede PRPThe hair loss workup before PRP, step by step — onset history, pattern recognition, trichoscopy, category-level labs, and the diagnoses
Train with Empire
This guide is clinical education. The technique behind it is taught hands-on, on live patients, with faculty beside you.
Explore PRP & Microneedling Training →Disclaimer
This article reflects the clinical opinions and experience of Tatiana Sarmiento, Empire Medical Training faculty, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.